Answers are grounded in this paper and cite their sources.
Antibiotic resistance is surging, demanding approaches that detect resistance before genetic fixation, since MIC, sequencing, and culture assays detect resistance late. We present Metabolomics-Driven Intervention Antibiotic Design (MDAD), which stages resistance evolution from metabolic compensation to sub-lethal adaptation to genetic fixation. A brief pulse challenge with a targeted metabolomics panel yields a pre-genetic risk index, interpreted with time-kill assays to situate early survival behaviours and guide mechanism-aware treatment and surveillance.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: